

***Decision Point: GF/B41/EDP13: Decision on the Secretariat’s Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2017-2019 Allocation Period***

The Board:

1. Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER09 (“Table 2”);
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

***This decision does not have material budgetary implications for operating expenses.***

**Table 2: Secretariat’s Recommendation on Additional Funding to Finance UOD from the 2017-2019 Allocation Period** - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Armenia	TB/HIV	ARM-C-MOH	Portfolio Optimization	USD	7,923,240	574,987	8,339,699
2	Mali	HIV	MLI-H-HCNLS	Portfolio Optimization	EUR	38,343,865	8,911,000	47,254,865
3	Mozambique	Malaria	MOZ-M-MOH	Portfolio Optimization	USD	126,235,937	2,202,469	128,438,406
			MOZ-M-WV	Portfolio Optimization	USD	41,634,402	1,475,436	43,109,838
4	Namibia	TB/HIV	NAM-C-MOH	Portfolio Optimization	USD	30,731,416	1,059,911	31,791,328